RO 7303509
Alternative Names: RG-6315 Roche; RO-7303509Latest Information Update: 28 Jun 2023
At a glance
- Originator Genentech
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic scleroderma
- No development reported Inflammation
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (IV)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (SC)
- 31 May 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a phase Ia trial in Inflammation presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)